StreetInsider.com News Articles

Pulse Biosciences sets up $85M at-the-market stock offering

Tue, 15 Sep 2026 16:46:29 -0400

Pulse Biosciences, Inc. (NASDAQ: PLSE) entered into an equity distribution agreement with Mizuho Securities USA LLC on September 15, 2026, allowing the company to sell up to $85,000,000 in common stock through at-the-market offerings on the Nasdaq Capital Market.

Under the agreement, Mizuho will act as sales agent and receive a commission of up to 3.0% of the gross sales price of any shares sold. The company is not obligated to sell any shares and may suspend solicitations at any time.

The new agreement follows a prior equity distribution agreement the company entered into with Mizuho on August 6, 2026, which allowed

Pulse Biosciences sets up $85M at-the-market stock offering

Tue, 15 Sep 2026 16:46:29 -0400

The new agreement follows a prior equity distribution agreement the company entered into with Mizuho on August 6, 2026, which allowed

Form 424B5 PULSE BIOSCIENCES, INC.

Tue, 15 Sep 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260915/27065462.html

Form 8-K PULSE BIOSCIENCES, INC. For: Sep 14

Tue, 15 Sep 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260915/27065469.html

Form 8-K PULSE BIOSCIENCES, INC. For: Sep 15

Tue, 15 Sep 2026 08:55:00 -0400

si-local-file:///var/storage/secattach/20260915/27061928.html

Pulse Biosciences completes 100-patient thyroid nodule study enrollment

Tue, 15 Sep 2026 07:01:40 -0400

Pulse Biosciences, Inc. (Nasdaq: PLSE) announced two milestones in its PRECISE-BTN clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules.

The company completed enrollment of 100 patients in August, double the study's original 50-patient design. Enrollment was conducted across three U.S. sites — Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine — over approximately 12 months.

Separately, the first patient enrolled in the study completed the final 12-month follow-up visit in August at Sarasota Memorial Health Care System in Sarasota, Florida, under the supervision of Ralph P. Tufano, MD, MBA,

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Tue, 15 Sep 2026 07:00:00 -0400

Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed 12-month follow-up

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (BTNs). The first patient enrolled in the study completed the final 12-month follow-up visit in August at Sarasota Memorial Health Care System in Sarasota, Florida, under the supervision of Ralph P. Tufano, MD, MBA, FACS.

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Tue, 15 Sep 2026 07:00:00 -0400

Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed 12-month follow-up

Freedom Capital Starts Pulse Biosciences (PLSE) at Buy

Wed, 09 Sep 2026 06:14:38 -0400

Freedom Capital analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $73.00.

The analyst comments "We initiate coverage of Pulse Biosciences (PLSE) with a BUY rating and $73 price target. Our bullish outlook is driven by several factors: (1) the AF ablation market is large, growing and disruptable, and we see nsPFA as a potentially significant disruptor; (2) PLSE has a prudent strategy, strong leadership and enough cash to fund operations through its most important catalyst, and; (3) if NANOPULSE-AF data in ~2Q27 is in-line with our expectations, we think there

Freedom Capital Starts Pulse Biosciences (PLSE) at Buy

Wed, 09 Sep 2026 06:14:38 -0400

Freedom Capital analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $73.00.

Form 4 PULSE BIOSCIENCES, INC. For: Aug 26 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:49:00 -0400

si-local-file:///var/storage/secattach/20260828/26999377.html

Form 4 PULSE BIOSCIENCES, INC. For: Aug 26 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:49:00 -0400

si-local-file:///var/storage/secattach/20260828/26999377.html

Form 4 PULSE BIOSCIENCES, INC. For: Apr 08 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:45:00 -0400

si-local-file:///var/storage/secattach/20260828/26999374.html

Form 4 PULSE BIOSCIENCES, INC. For: Apr 08 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:45:00 -0400

si-local-file:///var/storage/secattach/20260828/26999374.html

Form 3 PULSE BIOSCIENCES, INC. For: Apr 08 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:42:00 -0400

si-local-file:///var/storage/secattach/20260828/26999372.html

Form 3 PULSE BIOSCIENCES, INC. For: Apr 08 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:42:00 -0400

si-local-file:///var/storage/secattach/20260828/26999372.html

Form 4 PULSE BIOSCIENCES, INC. For: Feb 03 Filed by: Skinner Jon

Fri, 28 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260828/26999355.html

Form 4 PULSE BIOSCIENCES, INC. For: Feb 03 Filed by: Skinner Jon

Fri, 28 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260828/26999355.html

Form 3 PULSE BIOSCIENCES, INC. For: Feb 03 Filed by: Skinner Jon

Fri, 28 Aug 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260828/26999352.html

Form 3 PULSE BIOSCIENCES, INC. For: Feb 03 Filed by: Skinner Jon

Fri, 28 Aug 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260828/26999352.html

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 07:00:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on August 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 07:00:00 -0400

Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 07:00:00 -0400

Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 07:00:00 -0400

Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to

Needham Starts Pulse Biosciences (PLSE) at Buy

Mon, 17 Aug 2026 06:34:33 -0400

Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $58.00.

The analyst comments "PLSE has developed a differentiated next-generation pulse field ablation (PFA) platform technology, Nanosecond Pulsed Field Ablation (nsPFA). PLSE is targeting three applications of nsPFA: cardiac catheter ablation ($3.0B US, $8.0B global), cardiac surgical ablation ($1.8B US, $6.0B global), and benign thyroid lesion ablation ($1.3B US, $2.8B global). Early clinical results have been positive and PLSE is now running two pivotal studies. We expect clinical data and/or a partnership announcement to drive PLSE shares higher ahead of key